DuPage Medical Group

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Bladder cancer4 trials

Phase

• Phase 22 trials
• Phase 32 trials

Status

• Active, not recruiting3 trials
• Completed1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Pfizer1 trial

Running trials

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

  NCT04658862· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

Closed trials

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source